0
Mar 11, 2013, Vol 173, No. 5 >

Full Content is available to subscribers

Subscribe/Learn More
Commentary | Mar 11, 2013

The European Medicines Agency and the Brave New World of Access to Clinical Trial Data

Robert Steinbrook, MD
JAMA Intern Med. 2013;173(5):373-374. doi:10.1001/jamainternmed.2013.3842.
Text Size: A A A
Published online
Article
References
Comments

Extract

As of January 2014, the European Medicines Agency (EMA) will publish clinical trial data for the medications it considers for approval.1 After the marketing authorization process is complete, researchers and others who are independent of the sponsors of studies, the authors of journal reports, and regulatory agencies should be able to review complete study information, including anonymized data at the patient level, reanalyze the data, and conduct new analyses. If the EMA fulfills its promises, a new era of clinical trial data as a public good will begin.2 Data held by the agency will be available regardless of whether a trial is sponsored by industry, a medical research agency, or a foundation or initiated by investigators.

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

References

Correspondence

Submit a Letter
CME
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Clear Answers | Save For Later
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Compression-Only CPR: Pushing the Science Forward
Cone
AAM 2010;304:1493-1495.
All you need to read in the other general journals
BMJ 2010;341:c5893-c1494.
Submit a Comment

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Research Letters
The First 2 Years of the European Medicines Agency's Policy on Access to Documents: Secret No Longer
JAMA Intern Med. 2013;173(5):380-382. doi:10.1001/jamainternmed.2013.3838.
Research Letters
Impact of Attending Physician Workload on Patient Care: A Survey of Hospitalists
JAMA Intern Med. 2013;173(5):375-377. doi:10.1001/jamainternmed.2013.1864.
Research Letters
Patient Preferences for Deactivation of Implantable Cardioverter-Defibrillators
JAMA Intern Med. 2013;173(5):377-379. doi:10.1001/jamainternmed.2013.1883.
Invited Commentary
Defibrillators, Deactivation, Decisions, and Dying :  Comment on “Patient Preferences for Deactivation of Implantable Cardioverter-Defibrillators”
JAMA Intern Med. 2013;173(5):379-380. doi:10.1001/jamainternmed.2013.2130.
Research Letters
Using Information Technology to Improve the Monitoring of Outpatient Prescribing
JAMA Intern Med. 2013;173(5):382-384. doi:10.1001/jamainternmed.2013.2002.
Invited Commentary
Reaching Out to Patients to Identify Adverse Drug Reactions and Nonadherence:  Necessary but Not Sufficient
JAMA Intern Med. 2013;173(5):384-385. doi:10.1001/jamainternmed.2013.2965.
Research Letters
The Status of Baby Boomers' Health in the United States:  The Healthiest Generation?
JAMA Intern Med. 2013;173(5):385-386. doi:10.1001/jamainternmed.2013.2006.
Research Letters
Ascorbic Acid Supplements and Kidney Stone Incidence Among Men: A Prospective Study
JAMA Intern Med. 2013;173(5):386-388. doi:10.1001/jamainternmed.2013.2296.
Invited Commentary
The Risk of Taking Ascorbic Acid
JAMA Intern Med. 2013;173(5):388-389. doi:10.1001/jamainternmed.2013.2305.
Editor's Correspondence
Safety-Net Hospitals: Other Hospitals Score Similarly on Patient Experience
JAMA Intern Med. 2013;173(5):389-391. doi:10.1001/jamainternmed.2013.2158.
Editor's Correspondence
Safety-Net Hospitals: Other Hospitals Score Similarly on Patient Experience—Reply
JAMA Intern Med. 2013;173(5):389-391. doi:10.1001/jamainternmed.2013.2670.
Editor's Correspondence
Hospital Salt
JAMA Intern Med. 2013;173(5):391-392. doi:10.1001/jamainternmed.2013.2161.
Editor's Correspondence
Hospital Salt—Reply
JAMA Intern Med. 2013;173(5):391-392. doi:10.1001/jamainternmed.2013.2545.
Editor's Correspondence
Prostate-Specific Antigen for Prostate Cancer Screening: A Different Strategy Should Be Planned
JAMA Intern Med. 2013;173(5):392. doi:10.1001/jamainternmed.2013.2173.
Editor's Correspondence
Prostate Cancer Screening and Incidence: A Question of Causality
JAMA Intern Med. 2013;173(5):392-393. doi:10.1001/jamainternmed.2013.2164.
Editor's Correspondence
Prostate Cancer Screening and Incidence: A Question of Causality—Reply
JAMA Intern Med. 2013;173(5):392-393. doi:10.1001/jamainternmed.2013.2548.
Editor's Correspondence
Cultural Capital: Accounting for Power in Patient-Physician Interactions
JAMA Intern Med. 2013;173(5):393-394. doi:10.1001/jamainternmed.2013.2167.
Articles Related By Topic
Adulterated Sexual Enhancement Supplements:  More Than Mojo
JAMA Intern Med. 2013;():1-3. doi:10.1001/jamainternmed.2013.854.
The First 2 Years of the European Medicines Agency's Policy on Access to Documents: Secret No Longer
JAMA Intern Med. 2013;173(5):380-382. doi:10.1001/jamainternmed.2013.3838.
Related Topics
Jobs

More Listings at
JAMACareerCenter.com >

JAMAevidence.com

Users' Guides to the Medical Literature
For example, a trial of intravenous immunoglobulin in advanced human immunodeficiency infection...

The Rational Clinical Examination
Evidence Summary and Review 3

All results at
JAMAevidence.com >

© 2013 American Medical Association. All Rights Reserved.
Powered bySilverchair Information Systems